Search results
Results from the WOW.Com Content Network
Fresenius SE & Co. KGaA is a European multinational health care company based in Bad Homburg vor der Höhe, Germany. It provides products and services for dialysis in hospitals, as well as inpatient and outpatient medical care.
Fresenius Medical Care AG & Co. KGaA is a German healthcare company which provides kidney dialysis services through a network of 4,171 outpatient dialysis centers, serving 345,425 patients. [3] The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo dialysis 3 times per week for the rest of their lives.
Brandt started his professional career at PriceWaterhouse in Stuttgart, where he was employed from 1981 to 1992. He then served as a member of the executive board of Baxter Deutschland GmbH for seven years before becoming CFO and labor director of Fresenius Medical Care AG, where he served for two years.
Diversified Specialty Institute is a healthcare group created in 2003 with the purpose of building and operating hospitals nationwide. While the group's primary task is the operation of over a hundred dialysis clinics around the nation, DSI is involved in hospital construction technology with operations including a breast cancer treatment facility in Bucks County, Pennsylvania, United States ...
The second joint company of CSL Vifor with Fresenius is Vifor Fresenius Kabi focusing on marketing iron deficiency drugs in China. [27] CSL Vifor includes also Sanifit Therapeutics from Spain active in the field of calcification disorders in Chronic Kidney Disease. [28] Nephtera is a joint venture with Evotec to build a nephrology therapeutic ...
The hospital system has nearly 30,000 employees across South Carolina. The company had major layoffs in Jan. 2020 as well, when it laid off more than 300 people – just before the COVID-19 ...
Schneider joined Fresenius in November 2001, when he was appointed chief financial officer of Fresenius Medical Care. From May 2003 until June 2016 he was CEO of the parent company Fresenius. Under Schneider's leadership of Fresenius, the number of employees more than tripled, revenue quadrupled and net income increased twelvefold. [4]
From January 2008 to April 2011, if you bought shares in companies when David Owen joined the board, and sold them when she left, you would have a -7.3 percent return on your investment, compared to a -7.1 percent return from the S&P 500.